| Identification | Back Directory | [Name]
4-acetylphenyloxooxazolidinylmethylacetamide | [CAS]
104421-21-8 | [Synonyms]
DuP-721
4-acetylphenyloxooxazolidinylmethylacetamide
N-[[(5S)-3-(4-Acetylphenyl)-2-oxooxazolidin-5-yl]methyl]acetamide
N-[[(5S)-3-(4-Acetylphenyl)-2-oxooxazolidin-5α-yl]methyl]acetamide
N-[[(5S)-2-Oxo-3-(4-acetylphenyl)-5α-oxazolidinyl]methyl]acetamide | [Molecular Formula]
C14H16N2O4 | [MDL Number]
MFCD30564792 | [MOL File]
104421-21-8.mol | [Molecular Weight]
276.29 |
| Hazard Information | Back Directory | [Uses]
DuP-721 is a broad spectrum and orally active antibacterial agent against a variety of clinically susceptible and resistant bacteria, especially M. tuberculosis[1]. | [Biological Activity]
DuP-721 is a broad spectrum and orally active antibacterial agent against a variety of clinically susceptible and resistant bacteria, especially M. tuberculosis[1].
DuP-721 (1.5-4 μg/ml) inhibits equally the strains of Mycobacterium tuberculosis susceptible and resistant to conventional antituberculosis drug. And it does not show cross resistance to any of the anti-tuberculosis drugs tested[1].DuP-721 is inactive against M. avium and M. intracellulare at 250 μg/ml. It inhibits M. gordonoe and M. fortuitum at 3.9 μg/ml and M. kansassi and M. scrofulaceum at 1.95 μg/ml and 15.6 μg/ml, respectively[1].
DuP-721 (oral gavage; 50-160 mg/kg) is protective against M. tuberculosis infection in mice. DuP-721 protects 100% of the infected animals at 50 mg/kg p.o. dose when administered daily for 17 days, and the same effect is observed at 160 mg/kg dose when the drug is administered only on day 11 and 12 post infection[1]. | [in vivo]
DuP-721 (oral gavage; 50-160 mg/kg) is protective against M. tuberculosisinfection in mice. DuP-721 protects 100% of the infected animals at 50 mg/kg p.o. dose when administered daily for 17 days, and the same effect is observed at 160 mg/kg dose when the drug is administered only on day 11 and 12 post infection[1]. | [storage]
Store at -20°C | [References]
[1]. Affiliatio, et al. Antimycobacterial activities of oxazolidinones: a review. Infect Disord Drug Targets. 2006 Dec;6(4):343-54. |
|
|